A new US tariff on branded pharmaceuticals has sparked concerns for Indian drugmakers, particularly regarding branded generics and CDMOs. Market expert Sandip Sabharwal favors auto stocks like Maruti and M&M, anticipating benefits from rupee depreciation. He also cautions against the current IPO rush, deeming valuations too high and preferring to remain on the sidelines.